BioCryst reports Q2 2026 results, completes navenibart pivotal enrollment
BioCryst posted $218.3 million in total revenue and raised full-year revenue guidance as it finished enrollment in its pivotal navenibart study and began pediatric ORLADEYO pellet shipments.
SEC filing